Telavancin 750mg powder for solution for infusion vials

BACKGROUND: Vancomycin is a first-line drug for the treatment of MRSA infection. However, overuse of vancomycin can cause bacteria to become resistant, forming resistant strains and making infections more difficult to treat. This study aimed to evaluate the efficacy and safety of different antibiotics in the treatment of MRSA infections and to compare them, mainly with vancomycin, to find better vancomycin alternatives. METHODS: All studies were obtained from the PubMed and Embase databases from inception to 13 April 2023. The three comprehensive indicators of clinical cure success rate, clinical microbiological success rate, and adverse reactions were evaluated, and the clinical cure success rates of three disease types, complex skin and skin structure infections (cSSSIs), complex skin and soft tissue infections (cSSTIs), and pneumonia, were analyzed in subgroups. All statistical analyses were performed using R and STATA 14.0 software for network meta-analysis. RESULTS: A total of 38 trials with 6281 patients were included, and 13 drug treatments were evaluated. For MRSA infections, the results of network meta-analysis showed that the clinical success rates of linezolid, the combination of vancomycin and rifampin, and the combination of minocycline and rifampin were better than that of vancomycin (RR 1.71; 95%-CI 1.45-2.02), (RR 2.46; 95%-CI 1.10-5.49) (RR, 2.77; 95%-CI 1.06-7.21). The success rate of clinical microbiological treatment with vancomycin was inferior to that with telavancin (RR 0.74; 95%-CI 0.55-0.99). Linezolid had a higher rate of adverse reactions than teicoplanin (RR 5.35; 95%-CI 1.10-25.98). Subgroup analysis showed that vancomycin had a lower clinical success rate than linezolid in the treatment of MRSA-induced cSSSIs, cSSTIs, and pneumonia (RR 0.59; 95%-CI 0.44-0.80) (RR 0.55; 95%-CI 0.35-0.89) (RR 0.55; 95%-CI 0.32-0.93). CONCLUSIONS: This systematic review and NMA provide a new comparison framework for the clinical treatment of MRSA infection. The NMA suggests that linezolid may be the antibiotic of choice for the treatment of MRSA infections, with the ability to improve clinical and microbiological success rates despite its disadvantage in terms of adverse effects. At the same time, the combination of minocycline and rifampicin may be the most effective drug to treat MRSA-induced cSSSIs, tedizolid may be the best drug to treat MRSA-induced cSSTIs, and the combination of vancomycin and rifampicin may be the most effective treatment for MRSA-induced pneumonia. More high-quality studies are still needed in the future to further identify alternatives to vancomycin. TRIAL REGISTRATION: PROSPERO registration number CRD42023416788.

Abstract licence: CC BY

BACKGROUND: Few studies have compared the efficacy and safety of omadacycline with other treatments for acute bacterial skin and skin structure infections (ABSSSI). Therefore, updated meta-analyses on this topic is necessary. METHODS: We conducted a network meta-analysis (NMA) of randomized controlled trials (RCTs) to compare omadacycline with other anti-MRSA antibiotics. A systematic search of seven databases was undertaken to identify eligible RCTs enrolling adults with ABSSSI. Two reviewers independently assessed the quality of the included studies and three reviewers independently extracted data from all manuscripts. All meta-analyses were performed using R software. RESULTS: Our NMA included 39 RCTs with a total of 20,862 patients with ABSSSI. Eighteen anti-MRSA antibiotics were analyzed in the NMA. In terms of early clinical response, omadacycline was comparable to oxazolidinones like linezolid, tedizolid, and contezolid. Across various populations, including the intention-to-treat (ITT), modified ITT, and clinically evaluable populations, omadacycline showed higher or comparable clinical success rates, although these results were of borderline statistical significance. The results showed that omadacycline ranked first in efficacy among 18 antibiotics, based on surface under the cumulative ranking curve values. Additionally, omadacycline had significantly fewer serious adverse events than telavancin and demonstrated a safety profile comparable to other antibiotics. CONCLUSIONS: Our findings indicate that omadacycline is a promising treatment option for ABSSSI, demonstrating efficacy that is comparable to or potentially superior to many other anti-MRSA agents, along with a favorable safety profile. However, these results should be interpreted with caution due to the study's inherent limitations.

Abstract licence: CC BY-NC-ND

BACKGROUND: Methicillin-resistant Staphylococcus aureus (MRSA) is a major public health concern, particularly in resource-limited settings such as Africa. This meta-analysis aimed to determine the proportion of MRSA among S. aureus isolates from patients with confirmed infections and to assess associated antibiotic resistance profiles across the continent. METHODS: A comprehensive literature search was conducted in African Journals Online, African Index Medicus, PubMed, Scopus, Google Scholar, and Web of Science for studies published between January 1, 2013, and June 5, 2024. Primary studies were included if they reported MRSA proportion or resistance profiles in Africa, employed reliable detection techniques, and analyzed clinical specimens from infected patients. Statistical analyses were performed using the meta package in R software, applying a random-effects model. A p-value of < 0.05 was considered statistically significant. RESULTS: This meta-analysis included 191 studies, encompassing 40,979 S. aureus isolates. Nigeria contributed the highest number of studies (n = 29), followed by Egypt (n = 26). The vast majority of studies (n = 186) were based on hospital settings. The pooled proportion of MRSA in Africa was 42.2% (95% CI 38.7-45.6). By detection method, proportion was 41.4% for mecA, 42.8% for the cefoxitin disc method, and 39.1% for the oxacillin disc method, with no significant differences observed (p = 0.8). Regionally, Northern Africa had a significantly higher proportion of 56.2% (95% CI 49.3-62.9) compared with 36.7% (95% CI 33.2-40.4) in Sub-Saharan Africa (p < 0.001). At the country level, Eritrea reported the highest proportion (71.8%), followed by Egypt (61.8%), while the lowest rates were observed in Malawi (7.0%) and Gabon (8.2%). Regarding MRSA resistance profiles, linezolid (3.4%) and vancomycin (4.7%) showed the lowest resistance rates, whereas higher rates were noted for fusidic acid (11.6%), rifampin (28.4%), clindamycin (40.4%), trimethoprim-sulfamethoxazole (54.5%), and tetracycline (60.2%). Limited data were available for telavancin, dalbavancin, oritavancin, tedizolid, ceftaroline, mupirocin, and daptomycin. CONCLUSION: The proportion of MRSA in Africa remains high at 42.2%, with marked regional disparities. Although resistance rates for linezolid and vancomycin are relatively low, they surpass global averages, raising concerns about emerging resistance. Alarmingly high resistance rates to several other antibiotics further underscore the urgent need for targeted interventions and continuous surveillance.

Abstract licence: CC BY

PURPOSE: Vancomycin is the standard therapy for suspected or confirmed Methicillin-resistant Staphylococcus aureus (MRSA) skin and soft tissue infection (SSTI). Although newer anti-MRSA agents claim improved efficacy and safety, evidence in microbiologically confirmed MRSA-SSTI remains limited and heterogenous. Thus, this study aimed to systematically compare the efficacy and safety of alternative agents versus vancomycin in adults with confirmed MRSA-SSTI. METHODS: Three databases were searched until August 05, 2025, to retrieve randomized controlled trials (RCTs) from published meta-analyses evaluating vancomycin versus alternatives involving patients with MRSA-confirmed SSTI. Pooled risk ratios (RR) and 95% confidence intervals (CI) were calculated using random-effects model. The study is registered in PROSPERO (CRD420251119756). RESULTS: From 28 meta-analyses, 39 RCTs (n = 20,285; 2,662 patients with MRSA-confirmed SSTI receiving alternative agents and 2,322 receiving vancomycin) were included. No significant difference in clinical success was observed between groups (RR: 1.012, 95% CI: 0.992-1.032; prediction interval: 0.994-1.030). Although alternatives showed modestly higher microbiological success (RR: 1.058, 95% CI 1.001-1.119; prediction interval: 0.895-1.250), the effect lost significance after publication bias adjustment. Alternative agents had significantly lower dermatologic but higher gastrointestinal and hematological risk. Tigecycline had higher adverse events (RR: 1.090, 95% CI: 1.019-1.166), and telavancin had higher drug discontinuation (RR: 1.405, 95% CI: 1.105-1.786). CONCLUSION: Despite the growth of newer anti-MRSA agents, vancomycin remains clinically comparable for MRSA-confirmed SSTI, with apparent microbiological advantages of alternatives tempered by potential publication bias. Varying safety and pharmacological profiles of these agents emphasize the importance of individualized treatment selection.

Abstract licence: CC BY-NC-ND

Telavancin was discovered by modifying the chemical structure of vancomycin and belongs to the group of lipoglycopeptides. It employs its antimicrobial potential through two distinct mechanisms of action: inhibition of bacterial cell wall synthesis and induction of bacterial membrane depolarization and permeabilization. In this article we review the clinically relevant pharmacokinetic and pharmacodynamic data of telavancin. For comparison, the pharmacokinetic and pharmacodynamic data of the other glycopeptides are presented. Although, in contrast to the newer lipoglycopeptides, telavancin demonstrates a relatively short half-life and rapid total clearance, its apparent volume of distribution (Vd) is almost identical to that of dalbavancin. The accumulation of telavancin after repeated dosing is only marginal, whereas the pharmacokinetic values of the other glycopeptides show much greater differences after administration of multiple doses. Despite its high plasma–protein binding of 90% and relatively low Vd of approximately 11 L, telavancin shows near complete equilibration of the free fraction in plasma with soft tissue. The ratio of the area under the plasma concentration–time curve from time zero to 24 h (AUC24) of unbound plasma concentrations to the minimal inhibitory concentration (MIC) required to inhibit growth of 90% of organisms (MIC90) of Staphylococcus aureus and S. epidermidis of telavancin are sufficiently high to achieve pharmacokinetic/pharmacodynamic targets indicative for optimal bacterial killing. Considering both the AUC24/MIC ratios of telavancin and the near complete equilibration of the free fraction in plasma with soft tissue, telavancin is an appropriate antimicrobial agent to treat soft tissue infections caused by Gram-positive pathogens. Although the penetration of telavancin into epithelial lining fluid (ELF) requires further investigations, the AUC24/MIC ratio for S. aureus indicates that bactericidal activity in the ELF could be expected.

Abstract licence: CC BY-NC

Therapeutic drug monitoring (TDM) is a critical clinical tool used to optimize the safety and effectiveness of drugs by measuring their concentration in biological fluids. These fluids are primarily plasma or blood. TDM, together with real-time dosage adjustment, contributes highly to the successful management of glycopeptide antimicrobial therapies. Understanding pharmacokinetic/pharmacodynamic (PK/PD) properties is vital for optimizing antimicrobial therapies, as the efficacy of these therapies depends on both the exposure of the patient to the drug (PK) and pharmacodynamic (PD) parameters such as the in vitro estimated minimum drug concentration that inhibits bacterial growth (MIC). Liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) is widely recognized as the gold standard for measuring small molecules, such as antibiotics. This review provides a comprehensive overview of LC-MS/MS methods available for TDM of glycopeptide antibiotics, including vancomycin, teicoplanin, dalbavancin, oritavancin, and telavancin.

Abstract licence: CC BY-NC-ND